Progenics Pharma (PGNX) Files Presentation with SEC Challenging 'Flawed Arguments' by Velan Capital

June 24, 2019 8:11 AM

Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) today filed a presentation with the U.S. Securities and Exchange Commission (“SEC”) in connection with its upcoming 2019 Annual Meeting (“Annual Meeting”) scheduled for July 11, 2019. The presentation addresses Velan Capital, L.P.’s (“Velan”) latest flawed arguments and is intended to supplement the investor presentation Progenics filed with the SEC on June 21, 2019 detailing the Company’s historic and ongoing actions to enhance shareholder value.

In addition to highlighting a number of illogical, contradictory and categorically untrue statements made by Velan, the presentation makes clear that:

Your vote is important, no matter how many or how few shares you own. The Progenics Board strongly recommends that shareholders vote on the WHITE proxy card “FOR” all of Progenics’ experienced director nominees. If you need assistance voting your shares, please contact Progenics’ proxy solicitor MacKenzie Partners, Inc. toll-free at (800) 322-2885 or


Corporate News Hedge Funds Management Comments

Next Articles